NYSE:QGEN - Qiagen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $38.12 +0.70 (+1.87 %) (As of 09/19/2018 03:21 AM ET)Previous Close$37.42Today's Range$37.64 - $38.1752-Week Range$30.20 - $39.45Volume858,600 shsAverage Volume955,313 shsMarket Capitalization$8.56 billionP/E Ratio29.46Dividend YieldN/ABeta1.11 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. Receive QGEN News and Ratings via Email Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNYSE:QGEN CUSIPN/A Webwww.qiagen.com Phone31-77-355-6600 Debt Debt-to-Equity Ratio0.53 Current Ratio1.79 Quick Ratio1.62 Price-To-Earnings Trailing P/E Ratio29.46 Forward P/E Ratio28.66 P/E Growth2.32 Sales & Book Value Annual Sales$1.42 billion Price / Sales6.14 Cash Flow$2.3885 per share Price / Cash15.96 Book Value$11.13 per share Price / Book3.42 Profitability EPS (Most Recent Fiscal Year)$1.27 Net Income$40.39 million Net Margins5.26% Return on Equity12.22% Return on Assets6.07% Miscellaneous Employees4,688 Outstanding Shares228,230,000Market Cap$8.56 billion Qiagen (NYSE:QGEN) Frequently Asked Questions What is Qiagen's stock symbol? Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN." How were Qiagen's earnings last quarter? Qiagen NV (NYSE:QGEN) released its quarterly earnings data on Tuesday, July, 31st. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.01. The business earned $377.20 million during the quarter, compared to analyst estimates of $376.89 million. Qiagen had a return on equity of 12.22% and a net margin of 5.26%. View Qiagen's Earnings History. What price target have analysts set for QGEN? 10 analysts have issued 12-month target prices for Qiagen's stock. Their forecasts range from $38.00 to $43.00. On average, they anticipate Qiagen's share price to reach $39.60 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Qiagen. What is the consensus analysts' recommendation for Qiagen? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen. Who are some of Qiagen's key competitors? Some companies that are related to Qiagen include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), AveXis (AVXS), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), argenx (ARGX), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Repligen (RGEN), Halozyme Therapeutics (HALO) and Acceleron Pharma (XLRN). Who are Qiagen's key executives? Qiagen's management team includes the folowing people: Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 52)Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 49)Mr. John Gilardi, VP of Corp. Communications & Investor RelationsMr. Jean-Pascal Viola, Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VPDr. Annette Koch, Sr. VP & Chief HR Officer Has Qiagen been receiving favorable news coverage? News stories about QGEN stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qiagen earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Qiagen. How do I buy shares of Qiagen? Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $38.12. How big of a company is Qiagen? Qiagen has a market capitalization of $8.56 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $1.27 on an earnings per share basis. Qiagen employs 4,688 workers across the globe. How can I contact Qiagen? Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected] MarketBeat Community Rating for Qiagen (NYSE QGEN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 66 (Vote Outperform)Underperform Votes: 79 (Vote Underperform)Total Votes: 145MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/19/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?